Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
Inspira Technologies has announced the expansion of its HYLA blood sensor technology into personalized blood lab testing, enabling rapid detection of serious medical conditions. The HYLA technology is designed to streamline blood work processes in medical settings, potentially reducing costs and improving patient outcomes by minimizing delays in test results. Currently undergoing clinical evaluations at Sheba Hospital, this advancement aligns with Inspira’s broader strategy to innovate within the healthcare industry, with plans for FDA submission in 2025.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is an innovative medical technology company specializing in life support and respiratory treatment. They have developed the INSPIRA ART, an Augmented Respiration Technology aimed at transforming the $19 billion mechanical ventilation market by providing an alternative to traditional ventilators. The company’s HYLA blood sensor technology offers real-time continuous blood monitoring to assist physicians in patient care.
YTD Price Performance: 14.15%
Average Trading Volume: 150,051
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $22.21M
See more data about IINN stock on TipRanks’ Stock Analysis page.
